Drugmakers spent 20% more on DTC ads in 2015 than in 2014. Eli Lilly was the top spender, shelling out $220.4 million to promote Cialis, its erectile dysfunction drug.
How to win an MM&M award: the do’s and the don’ts
April 1, 2016
1:00 pm
Tip: Don’t charge your intern with assembling your entry. Read more from our checklists of do’s and don’ts, and don’t forget that entries are due April 11.
Healthcare industry seeks to reform its position as hacking target
Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.
Drugmakers move to counteract expiring patents with new respiratory drugs
Symptom-driven care is falling out of favor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.
Corbus bets on cystic-fibrosis market with Resunab
Current treatments, including steroids and ibuprofen, help control symptoms. But the side-effect profiles are difficult for patients to manage.
Top 25 respiratory products, 2014-2015
March 28, 2016
12:50 pm
GlaxoSmithKline’s Advair brought in $4.8 billion in U.S. sales in 2015, edging out Boehringer Ingelheim’s Spiriva Handihaler ($3.4 billion) and AstraZeneca’s Symbicort ($2.6 billion).
Politics led to DTC uproar, but curbs unlikely in current climate
The motivating force behind My GI Health met initial resistance. After all, it came from a company executive who professed that his goal was to benefit all companies within that therapeutic area.
Ironwood’s McCourt bets big on data and the patient-physician dialogue
The regulator’s reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today’s precision medicine.
